HS 10511
Alternative Names: HS-10511Latest Information Update: 29 Jan 2024
At a glance
- Originator Jiangsu Hansoh Pharmaceutical; Shanghai Hansoh Biomedical
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypertrophic cardiomyopathy
Most Recent Events
- 29 Jan 2024 Jiangsu Hansoh Pharmaceutical plans a phase I trial for Hypertrophic cardiomyopathy (In Volunteers) in January 2024 (PO) (NCT06210607)
- 10 Nov 2023 National Medical Products Administration of the People's Republic of China grants a clinical trial notice for HS-10511
- 10 Nov 2023 Preclinical trials in Hypertrophic cardiomyopathy in China (PO) prior to November 2023